Product development issues for PEGylated proteins.
Covalent attachment of poly(ethylene) glycol (PEG) groups to proteins, a process commonly called PEGylation, is often used to improve the performance of a protein in vivo. To date, at least eight such PEGylated peptide and protein conjugates have been approved as therapeutic agents and many more have undergone clinical trials. This review examines PEGylation from the perspective of developing a commercially viable drug product. The first section focuses on obtaining a pure and well-characterized drug substance. The latter section discusses formulation and manufacturing issues, with an emphasis on analytical methodology that provides the most detailed description of the purity and stability of PEGylated proteins.
Payne
Robert W
RW
Legacy BioDesign LLC, Johnstown, Colorado 80534, USA.
Murphy
Brian M
BM
Manning
Mark Cornell
MC
D002623:Chemistry Techniques, Analytical / Q000379:methods*; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D006801:Humans; D010455:Peptides / Q000737:chemistry / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000493:pharmacokinetics; D055550:Protein Stability; D011506:Proteins / Q000737:chemistry* / Q000493:pharmacokinetics
D010455:Peptides; D011506:Proteins; D011092:Polyethylene Glycols